SBRT with immunotherapy and chemo for early-stage triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer (ER-, PR-, HER2-).
- Your tumor is stage T1c with 1-2 positive lymph nodes, or stage T2 with any lymph node involvement up to N2, and no distant spread (M0).
- You are in good physical condition (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and heart function are within study limits.
- You are not pregnant and agree to use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This trial tests a new way to treat triple-negative breast cancer before surgery by combining radiation therapy with an immunotherapy drug and chemotherapy. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy, an immunotherapy drug, and two different schedules of radiation before surgery for a common type of breast cancer. The goal is to find which radiation approach works better and to improve outcomes.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.